Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis Qiufan ZhengWen XiaShusen Wang Review 23 September 2016 Pages: 197 - 209
The 2016 Assisi Think Tank Meeting on breast cancer: white paper Cynthia AristeiOrit Kaidar-PersonPhilip M. P. Poortmans Review 29 September 2016 Pages: 211 - 221
Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis Jill Brook HervikTrine Stub Review Open access 05 October 2016 Pages: 223 - 236
High extent of O-GlcNAcylation in breast cancer cells correlates with the levels of HAS enzymes, accumulation of hyaluronan, and poor outcome Satu TiainenSanna OikariPäivi Auvinen Preclinical Study 28 September 2016 Pages: 237 - 247
A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression Nathalie ReixCharlotte MalinaCarole Mathelin Preclinical Study Open access 05 October 2016 Pages: 249 - 259
Treatment with aromatase inhibitors and markers of cardiovascular disease Eva BlondeauxDebora MusioLucia Del Mastro Clinical Trial 23 September 2016 Pages: 261 - 267
Use of a prospective surveillance model to prevent breast cancer treatment-related lymphedema: a single-center experience Eun Joo YangSoyeon AhnSung-Won Kim Clinical trial Open access 24 September 2016 Pages: 269 - 276
Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer Thomas M. DeutschSabine RiethdorfMarkus Wallwiener Clinical trial 01 October 2016 Pages: 277 - 290
Adjuvant radiation use in older women with early-stage breast cancer at Johns Hopkins YaoYao G. PollockAmanda L. BlackfordVered Stearns Clinical trial 03 October 2016 Pages: 291 - 296
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) Mehra GolshanConstance T. Cirrincionefor the Alliance for Clinical Trials in Oncology Clinical trial 04 October 2016 Pages: 297 - 304
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study Sara M. TolaneyHovav NechushtanEric P. Winer Clinical trial Open access 06 October 2016 Pages: 305 - 312
Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer Anna NordenskjöldHelena FohlinOlle Stål Clinical trial Open access 08 October 2016 Pages: 313 - 322
Breast cancer screening initiation after turning 40 years of age within the PROSPR consortium Elisabeth F. BeaberAnna N. A. TostesonWilliam E. Barlow Epidemiology 24 September 2016 Pages: 323 - 331
Equivalent survival after nipple-sparing compared to non-nipple-sparing mastectomy: data from California, 1988–2013 Allison W. KurianAlison J. CancholaChristina A. Clarke Epidemiology 24 September 2016 Pages: 333 - 338
Prognostic models in male breast cancer Carmen C. van der PolMiangela M. LaclePaul J. van Diest Epidemiology Open access 26 September 2016 Pages: 339 - 346
The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis Emily K. HartmanGuy D. Eslick Epidemiology 28 September 2016 Pages: 347 - 360
The association between China’s Great famine and risk of breast cancer according to hormone receptor status: a hospital-based study Aliya AlimujiangMiao MoGraham A Colditz Epidemiology 01 October 2016 Pages: 361 - 369
Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients Zibo LiJianfu HengJun Wang Epidemiology 08 October 2016 Pages: 371 - 383
Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer Christine LeopoldAnita K. WagnerJ. Frank Wharam Erratum 30 September 2016 Pages: 385 - 385